Patient adherence continues to represent a persistent challenge in the management of chronic diseases, despite increasing investment in home-based therapies and self-administration devices. Against this backdrop, Gerresheimer has introduced Gx InMonit, a connected add-on designed to support patients using autoinjector-based treatments.
The reusable device, compatible with platforms such as Gx Inbeneo, sits on top of the autoinjector and is designed to guide patients through each step of the injection process. A high-contrast display combined with audible signals provides real-time feedback, while embedded motion sensors detect key events including injection start, interruption, or premature removal. The aim, according to the company, is to reduce user error and support adherence to prescribed regimens.
Beyond guidance, Gx InMonit also captures data directly at the point of administration. Features such as temperature monitoring and NFC-based verification of the device, drug, and dose are intended to ensure traceability and accuracy. The data is automatically transmitted via cellular connectivity, removing the need for companion apps or manual input, an approach that may help reduce user friction, a known barrier in digital health adoption.
The device is designed to operate in conjunction with Gx AdheraLink, an AI-driven messaging solution that interacts with patients via widely used platforms such as WhatsApp or iMessage. Positioned as a low-friction engagement tool, the system delivers reminders ahead of injections and follow-up messages afterwards, while also enabling patients to report qualitative feedback on their experience.
Gerresheimer points to the scale of the adherence challenge to support its approach. “Adherence to prescribed therapy regimens in developed countries is as low as 50%,” said Mithun Ratnakumar, Director Digitalization and New Business Models at Gerresheimer Advanced Technologies, citing WHO data. He added that digital solutions combining device data and patient interaction could contribute to improved outcomes and lower healthcare costs.
More broadly, the launch reflects a growing convergence between drug delivery devices and digital health platforms. By combining objective adherence data with patient-reported inputs, such systems align with increasing demand from pharmaceutical companies for real-world evidence and more granular insights into patient behaviour outside clinical settings.
Gerresheimer positions the Gx InMonit–Gx AdheraLink combination as part of a wider ecosystem approach to therapy support. It complements existing solutions such as Gx® Cap, developed for oral medications and deployed in the US through Centor’s remote monitoring services.
While the impact of such tools will ultimately depend on adoption and integration into care pathways, the direction is clear: connected, data-enabled drug delivery is becoming a central component of strategies aimed at closing the adherence gap.